We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+15.91%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$177M
AUM Growth
-$15.4M
(-8%)
Cap. Flow
-$26.3M
Cap. Flow
% of AUM
-14.81%
Top 10 Holdings %
Top 10 Hldgs %
53.79%
Holding
76
New
22
Increased
8
Reduced
9
Closed
31
Avg Time Held Equity + Options
1.9
quarters
Top 10 Avg Time Held Equity + Options
1.6
quarters
Top 20 Avg Time Held Equity + Options
1.3
quarters
Avg Time Held Equity only
2.5
quarters
Top 10 Avg Time Held Equity only
2
quarters
Top 20 Avg Time Held Equity only
2.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$6.61M |
| 2 |
GSK
GSK
|
+$5.7M |
| 3 |
Eli Lilly
LLY
|
+$4.59M |
| 4 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$4.49M |
| 5 |
Boston Scientific
BSX
|
+$4.13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DMK
DMK Pharmaceuticals Corporation Common Stock
DMK
|
+$10.1M |
| 2 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$7.7M |
| 3 |
Biogen
BIIB
|
+$4.87M |
| 4 |
QTNT
Quotient Limited Ordinary Shares
QTNT
|
+$4.41M |
| 5 |
Globus Medical
GMED
|
+$4.38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.98% |
| 2 | Miscellaneous | 40.16% |
| 3 | Financials | 5.91% |
| 4 | Technology | 0.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
DELISTED
Sage Therapeutics
SAGE
| $29.5M | 16.65% |
179,200
-11,200
| -6% | -$1.09M |
2017 Q1
3 quarters
|
|
|
2
GSK
GSK
$92.7B
| $11.6M | 6.52% |
260,658
+123,303
| +90% | +$5.7M |
2016 Q4
4 quarters
|
|
|
AET
3
DELISTED
Aetna Inc
AET
| $10.5M | 5.91% |
58,089
+7,566
| +15% | +$1.3M |
2016 Q4
4 quarters
|
|
|
4
Elevance Health
ELV
$92.2B
| $10M | 5.64% |
44,446
+31,028
| +231% | +$6.61M |
2017 Q2
2 quarters
|
|
|
QTNT
5
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $7.06M | 3.98% |
35,653
-22,955
| -39% | -$4.41M |
2014 Q4
12 quarters
|
|
6
Kura Oncology
KURA
$874M
| $6M | 3.38% |
392,027
+116,296
| +42% | +$1.71M |
2017 Q3
1 quarter
|
|
7
PUT
Intuitive Surgical
ISRG
$149B
| $5.84M | 3.29% |
48,000
+25,500
| +113% | +$3.19M |
2017 Q2
2 quarters
|
|
8
Viking Therapeutics
VKTX
$3.39B
| $5.08M | 2.86% |
+1,250,250
| New | +$3.63M |
2017 Q4
0 quarters
|
|
9
CALL
Everforth Inc
EFOR
$1.57B
| $4.95M | 2.79% |
+77,000
| New | +$4.66M |
2017 Q4
0 quarters
|
|
10
CALL
Cardinal Health
CAH
$55.5B
| $4.9M | 2.76% |
+80,000
| New | +$4.95M |
2017 Q4
0 quarters
|
|
11
CALL
TriNet
TNET
$3.06B
| $4.88M | 2.75% |
+110,000
| New | +$4.4M |
2017 Q4
0 quarters
|
|
12
CALL
DELISTED
Premier
PINC
| $4.67M | 2.63% |
+160,000
| New | +$4.93M |
2017 Q4
0 quarters
|
|
|
WCG
13
DELISTED
Wellcare Health Plans, Inc.
WCG
| $4.67M | 2.63% |
+23,200
| New | +$4.49M |
2017 Q4
0 quarters
|
|
|
14
Eli Lilly
LLY
$1.04T
| $4.55M | 2.57% |
+53,900
| New | +$4.59M |
2017 Q4
0 quarters
|
|
15
CALL
UnitedHealth
UNH
$339B
| $4.41M | 2.49% |
+20,000
| New | +$4.24M |
2017 Q4
0 quarters
|
|
16
Emergent Biosolutions
EBS
$354M
| $4.25M | 2.4% |
91,533
+1,265
| +1% | +$53.2K |
2017 Q3
1 quarter
|
|
|
17
Boston Scientific
BSX
$62.8B
| $3.71M | 2.09% |
+149,752
| New | +$4.13M |
2017 Q4
0 quarters
|
|
18
CALL
HCA Healthcare
HCA
$99.8B
| $3.7M | 2.09% |
+42,100
| New | +$3.38M |
2017 Q4
0 quarters
|
|
19
PUT
Pfizer
PFE
$162B
| $3.62M | 2.04% |
+105,400
| New | +$3.59M |
2017 Q4
0 quarters
|
|
20
Rigel Pharmaceuticals
RIGL
$881M
| $3.43M | 1.94% |
88,506
-67,825
| -43% | -$2.58M |
2016 Q1
7 quarters
|
|
21
Pediatrix Medical
MD
$2.16B
| $3.02M | 1.71% |
+56,598
| New | +$2.67M |
2017 Q4
0 quarters
|
|
22
Gyre Therapeutics
GYRE
$711M
| $2.76M | 1.56% |
26,971
-29,247
| -52% | -$1.49M |
2017 Q2
2 quarters
|
|
23
DELISTED
Advanced Accelerator Applications S.A.
AAAP
| $2.67M | 1.51% |
32,736
-19,846
| -38% | -$1.54M |
2015 Q4
8 quarters
|
|
24
Icon
ICLR
$12.7B
| $2.65M | 1.49% |
23,604
| – | – |
2017 Q3
1 quarter
|
|
25
Philips
PHG
$24.3B
| $2.56M | 1.45% |
89,359
| – | – |
2016 Q1
7 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q4 2017 Portfolio in Review
As of Q4 2017, Sio Capital Management held 76 positions worth $177M, down 8% from $193M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Sio Capital Management withdrew a net $26.3M in Q4 2017, closing 31 positions and reducing 9 holdings. Its most notable exit was DMK Pharmaceuticals Corporation Common Stock, an estimated $10.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 60% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Sio Capital Management opened a new position in Eli Lilly worth $4.55M.
- Sio Capital Management's largest Q4 2017 buy was Eli Lilly: 53,900 shares worth $4.55M.
- Sio Capital Management added most to Elevance Health in Q4 2017, an estimated $6.61M increase.
- Sio Capital Management's biggest Q4 2017 reduction was Quotient Limited Ordinary Shares, cutting an estimated $4.41M.
- Sio Capital Management fully exited DMK Pharmaceuticals Corporation Common Stock in Q4 2017, selling an estimated $10.1M.
- Sio Capital Management's ten largest holdings make up 54% of its $177M portfolio in Q4 2017.
- Sio Capital Management opened 22 new positions and closed 31 in Q4 2017.
- Sio Capital Management's portfolio value fell 8% quarter-over-quarter to $177M.
Based on Sio Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.